



NeoCore Technology Co., Ltd. Investor Conference

2025/12/23



Disclaimer

The content of this presentation contains forecasts for future operations, which are affected by uncertainties such as the macroeconomy, market demand, and regulatory changes.

Actual results may differ from forward-looking statements. The company is not obligated to update or revise this content.

Note: Investment involves risks; investors should evaluate carefully.




Company Profile

The company has transitioned to focusing on "IVD Testing Technology" + "All-around Medical Aesthetic Solutions".

IVD Business :

Driven by technical expertise and policy tailwinds




Medical Aesthetic Solutions :

Deepening market channels and professional equipment offerings






Technological Moat : DR. Aim Platform



Technical Principle: Nucleic acid probes of specific sequences are fixed on a substrate. After processing and amplifying the sample, a hybridization reaction occurs on the chip. Signals are presented via chemical chromogenic methods to complete sample analysis.



高通量 (High Throughput)
Analyze multiple targets from a single sample simultaneously.

高效率 (High Efficiency)
Simplifies traditional testing workflows and shortens turnaround time.



低成本 (Low Cost)
The platform design is cost-effective, enhancing market competitiveness.

The 'DR. Aim Platform' is characterized by its **cost-efficiency** and **streamlined workflow**.



Technological Moat : DR. Aim Platform

臨床診斷 (Clinical Diagnostics)



- HPV Genotyping Test Kit.
- MTBC/NTM (Tuberculosis) Test Kit.

食品安全 (Food Safety)



- Food Pathogen (Enterobacteriaceae) Detection Chip.
- Ractopamine Rapid Test Strip.

自動化設備 (Automation Equipment)



- DR. Aim Reader (Rapid testing reagent reader).
- DR. Fluidic Station (Microplate automatic washer).



Policy Dividends : Structural Growth in HPV Market



Market Pain Point:

The incidence of cervical cancer in women over 65 is 2.4 times that of other age groups, highlighting an urgent need for screening

Government Policy:

Starting in 2025, public subsidies for HPV testing will expand to include women aged 35, 45, and 65.




Our Solutions:

- **Product Advantage:** Comprehensive testing for 27 HPV genotypes (15 high-risk / 12 medium-to-low risk).
- **Strategic Layout:** Actively capturing the "One Smear, Two Screenings" market trend and planning self-sampling brushes to increase screening willingness.



Precisely Capturing Market Trends : HPV products are the main source of IVD revenue.





Acquisition of 『VICTORY EIGHT ENTERPRISE CO., LTD.』

Major Event: Completed the acquisition of subsidiary "Ba Yi Industrial Co., Ltd." on January 2, 2025.



Market Expansion: Successfully entered the high-end medical aesthetic equipment market, including non-invasive treatments like "Mosaic 3D".



Revenue Diversification: Reducing reliance on a single market and establishing a second stable growth curve.






Mosaic 3D Fractional Laser




Technical Highlights:

- **3D Control Chaos Technology (AI):** Precisely calculates energy density and treatment depth for personalized care.
- **No Open Wounds:** Balances comfort and efficacy, meeting modern demands for rapid recovery.



Clinical Indications:



- Improving shallow/loose skin ("Glycation Skin")
- Structural pore reconstruction
- Improving skin quality in thin areas (eyes, neck)



All-around Medical Aesthetic Portfolio

Improving
sallow/loose skin
("Glycation Skin")



PICOPLUS 4D
(Picosecond Laser)

Specifically designed for Asian skin to improve deep spots and uneven tone.



GENIUS
(Radiofrequency
Microneedling)

Addresses aging issues through layered therapy to achieve skin tightening.



CLARITY II
(Dual Wavelength Laser)


Utilizes dual-wavelength pulse technology to simultaneously solve vascular and pigment deposition issues.



Revenue Trend

Note: The company overall remains in a loss-making state; investors should remain cautious.

Unit : NT\$ Thousand




The primary growth is driven by the contribution of medical equipment sales revenue following the acquisition of the subsidiary, VICTORY EIGHT ENTERPRISE CO., LTD.



Revenue Structure


Note: The company overall remains in a loss-making state; investors should remain cautious.






Gross Margin% and Net Income

Note: The company overall remains in a loss-making state; investors should remain cautious.





Conclusion & Outlook



Deepening IVD Core Business



Market Penetration: Capture government subsidy policies to expand market share.



Technical Upgrade: Invest in automation (robotic arms) to solve labor shortages and widen the competitive gap.



Product Expansion: Develop Thin-prep Cytology (TCT) preservative solution by 2026 to achieve the "One Smear, Two Screenings" trend.

Expanding Medical Aesthetic Footprint



Channel Integration: Leverage the subsidiary's existing channel advantages for rapid market distribution.



Brand Synergy: Integrate group resources to enhance brand awareness and market influence.



Technology Introduction: Continuously evaluate and introduce innovative equipment with high market potential.



Thank You